Post-Glycosylation Modification of Sialic Acid and Its Role in Virus
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
A Mouse B16 Melanoma Mutant Deficient in Glycolipids
Proc. Natl. Acad. Sci. USA Vol. 91, pp. 2703-2707, March 1994 Biochemistry A mouse B16 melanoma mutant deficient in glycolipids (glucosyltransferase/glucosylceramide/glucocerebroside) SHINICHI ICHIKAWA*t, NOBUSHIGE NAKAJO*, HISAKO SAKIYAMAt, AND YOSHIo HIRABAYASHI* *Laboratory for Glyco Cell Biology, Frontier Research Program, The Institute of Chemical and Physical Research (RIKEN), 2-1 Hirosawa, Wako-shi, Saitama 351-01, Japan; and *Division of Physiology and Pathology, National Institute of Radiological Sciences, 4-9-1 Anagawa, Chiba-shi, Chiba 260, Japan Communicated by Saul Roseman, December 21, 1993 ABSTRACT Mouse B16 melanoma cell line, GM-95 (for- cosyltransferase would provide an ideal tool. Although sev- merly designated as MEC-4), deficient in sialyllactosylceram- eral glycosylation mutant cells have been isolated by treat- ide was examined for its primary defect. Glycolipids from the ment with a mutagen followed by selection with lectins, mutant cells were analyzed by high-performance TLC. No defects in these mutants were involved in either glycoprotein glycolipid was detected in GM-95 cells, even when total lipid syntheses (for review, see ref. 3), nucleotide sugar syntheses, from 107 cells was analyzed. In contrast, the content of or nucleotide sugar transporters (4). Mutants defective in ceramide, a precursor lipid molecule of glycolipids, was nor- glycolipid-specific transferases have rarely been found. Re- mal. Thus, the deficiency of glycolipids was attributed to the cently, Tsuruoka et al. (5) isolated a mouse mammary car- first glucosylation step of ceramide. The ceramide glucosyl- cinoma mutant that gained GM3 expression by selection with transferase (EC 2.4.1.80) activity was not detected in GM-95 antilactosylceramide (anti-LacCer) monoclonal antibody cells. -
Regulation of Glycolipid Synthesis in HL-60 Cells by Antisense
Proc. Natl. Acad. Sci. USA Vol. 92, pp. 8670-8674, September 1995 Neurobiology Regulation of glycolipid synthesis in HL-60 cells by antisense oligodeoxynucleotides to glycosyltransferase sequences: Effect on cellular differentiation (gangliosides/gene expression/cell maturation) GuicHAo ZENG, TOSHlo ARIGA, XIN-BIN Gu, AND ROBERT K. Yu* Department of Biochemistry and Molecular Biophysics, Medical College of Virginia, Virginia Commonwealth University, Richmond, VA 23298-0614 Communicated by Saul Roseman, Johns Hopkins University, Baltimore, MD, June 8, 1995 ABSTRACT Treatment of the human promyelocytic leuke- Gal1-Gic-Cer mia cell line HL-60 with antisense oligodeoxynucleotides to UDP-N-acetylgalactosamine: 3-1,4-N-acetylgalactosaminyl- transferase (GM2-synthase; EC 2.4.1.92) and CMP-sialic acid:a- GGM3 synd8s EC 2.4.99.8) sequences ef- 2,8-sialyltransferase (GD3-synthase; Gal-Glc-Cer GD3 synthase Grl-Glc-Cer fectively down-regulated the synthesis of more complex ganglio- SA - SA sides in the ganglioside synthetic pathways after GM3, resulting cm sA aon in a remarkable increase in endogenous GM3 with concomitant decreases in more complex gangliosides. The treated cells un- GM2 synthase derwent monocytic differentiation as judged by morphological clwiges, adherent ability, and nitroblue tetrazolium staining. GaiNAc-Gal-Glc-Cer GaINAc-Gal-Glc-Cer SA These data provide evidence that the increased endogenous sk Q ganglioside GM3 may play an important role in regulating IGM2 SA cellular differentiation and that the antisense DNA technique proves to be a powerful tool in manipulating glycolipid synthesis GalGaNAc-Ca-Glc-Cer Gal-GaINAc-Gal-Glc-Cer in the cell. SA SA SA GDlb The composition of gangliosides-in cells undergoes dramatic changes during cellular growth, differentiation, and oncogenic transformation, suggesting a specific role of gangliosides in the Gal-GaINAc-Gal-Gic-Cer Gal-GaINAc-Gal-Glc-Cer regulation of these cellular events (3-5). -
Terminal Sialic Acid Linkages Determine Different Cell Infectivities of Human Parainfluenza Virus Type 1 and Type 3
Virology 464-465 (2014) 424–431 Contents lists available at ScienceDirect Virology journal homepage: www.elsevier.com/locate/yviro Terminal sialic acid linkages determine different cell infectivities of human parainfluenza virus type 1 and type 3 Keijo Fukushima a,1, Tadanobu Takahashi a,1, Seigo Ito a, Masahiro Takaguchi a, Maiko Takano a, Yuuki Kurebayashi a, Kenta Oishi a, Akira Minami a, Tatsuya Kato b,f, Enoch Y Park b,e,f, Hidekazu Nishimura c, Toru Takimoto d, Takashi Suzuki a,n a Department of Biochemistry, School of Pharmaceutical Sciences, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka 4228526, Japan b Laboratory of Biotechnology, Department of Applied Biological Chemistry, Faculty of Agriculture, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 4228529, Japan c Virus Research Center, Sendai Medical Center, 2-8-8 Miyagino, Miyagino-ku, Sendai, Miyagi 9838520, Japan d Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY 14642, USA e Laboratory of Biotechnology, Integrated Bioscience Section, Graduate School of Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 4228529, Japan f Laboratory of Biotechnology, Green Chemistry Research Division, Research Institute of Green Science and Technology, Shizuoka University, 836 Ohya, Suruga-ku, Shizuoka 4228529, Japan article info abstract Article history: Human parainfluenza virus type 1 (hPIV1) and type 3 (hPIV3) initiate infection by sialic acid binding. Received 22 May 2014 Here, we investigated sialic acid linkage specificities for binding and infection of hPIV1 and hPIV3 by Returned to author for revisions using sialic acid linkage-modified cells treated with sialidases or sialyltransferases. The hPIV1 is bound to 8 July 2014 only α2,3-linked sialic acid residues, whereas hPIV3 is bound to α2,6-linked sialic acid residues in Accepted 11 July 2014 addition to α2,3-linked sialic acid residues in human red blood cells. -
GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies
International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy. -
Sialic Acids and Their Influence on Human NK Cell Function
cells Review Sialic Acids and Their Influence on Human NK Cell Function Philip Rosenstock * and Thomas Kaufmann Institute for Physiological Chemistry, Martin-Luther-University Halle-Wittenberg, Hollystr. 1, D-06114 Halle/Saale, Germany; [email protected] * Correspondence: [email protected] Abstract: Sialic acids are sugars with a nine-carbon backbone, present on the surface of all cells in humans, including immune cells and their target cells, with various functions. Natural Killer (NK) cells are cells of the innate immune system, capable of killing virus-infected and tumor cells. Sialic acids can influence the interaction of NK cells with potential targets in several ways. Different NK cell receptors can bind sialic acids, leading to NK cell inhibition or activation. Moreover, NK cells have sialic acids on their surface, which can regulate receptor abundance and activity. This review is focused on how sialic acids on NK cells and their target cells are involved in NK cell function. Keywords: sialic acids; sialylation; NK cells; Siglecs; NCAM; CD56; sialyltransferases; NKp44; Nkp46; NKG2D 1. Introduction 1.1. Sialic Acids N-Acetylneuraminic acid (Neu5Ac) is the most common sialic acid in the human organism and also the precursor for all other sialic acid derivatives. The biosynthesis of Neu5Ac begins in the cytosol with uridine diphosphate-N-acetylglucosamine (UDP- Citation: Rosenstock, P.; Kaufmann, GlcNAc) as its starting component [1]. It is important to understand that sialic acid T. Sialic Acids and Their Influence on formation is strongly linked to glycolysis, since it results in the production of fructose-6- Human NK Cell Function. Cells 2021, phosphate (F6P) and phosphoenolpyruvate (PEP). -
Review Sialic Acid-Specific Lectins: Occurrence, Specificity and Function
Cell. Mol. Life Sci. 63 (2006) 1331–1354 1420-682X/06/121331-24 DOI 10.1007/s00018-005-5589-y Cellular and Molecular Life Sciences © Birkhäuser Verlag, Basel, 2006 Review Sialic acid-specific lectins: occurrence, specificity and function F. Lehmanna, *, E. Tiralongob and J. Tiralongoa a Institute for Glycomics, Griffith University (Gold Coast Campus), PMB 50 Gold Coast Mail Centre Australia 9726 (Australia), Fax: +61 7 5552 8098; e-mail: [email protected] b School of Pharmacy, Griffith University (Gold Coast Campus), PMB 50 Gold Coast Mail Centre Australia 9726 (Australia) Received 13 December 2005; received after revision 9 February 2006; accepted 15 February 2006 Online First 5 April 2006 Abstract. Sialic acids consist of a family of acidic nine- through specific interactions with lectins, a family of carbon sugars that are typically located at the terminal po- proteins that recognise and bind sugars. This review will sitions of a variety of glycoconjugates. Naturally occur- present a detailed overview of our current knowledge re- ring sialic acids show an immense diversity of structure, garding the occurrence, specificity and function of sialic and this reflects their involvement in a variety of biologi- acid-specific lectins, particularly those that occur in vi- cally important processes. One such process involves the ruses, bacteria and non-vertebrate eukaryotes. direct participation of sialic acids in recognition events Keywords. Sialic acid, lectin, sialoglycoconjugate, sialic acid-specific lectin, adhesin, infectious disease, immunology. Introduction [1, 2]. The largest structural variations of naturally occurring Sia are at carbon 5, which can be substituted with either an Sialic acids (Sia) are a family of nine-carbon a-keto acids acetamido, hydroxyacetamido or hydroxyl moiety to form (Fig. -
Mouse Model of GM2 Activator Deficiency Manifests Cerebellar Pathology and Motor Impairment
Proc. Natl. Acad. Sci. USA Vol. 94, pp. 8138–8143, July 1997 Medical Sciences Mouse model of GM2 activator deficiency manifests cerebellar pathology and motor impairment (animal modelyGM2 gangliosidosisygene targetingylysosomal storage disease) YUJING LIU*, ALEXANDER HOFFMANN†,ALEXANDER GRINBERG‡,HEINER WESTPHAL‡,MICHAEL P. MCDONALD§, KATHERINE M. MILLER§,JACQUELINE N. CRAWLEY§,KONRAD SANDHOFF†,KINUKO SUZUKI¶, AND RICHARD L. PROIA* *Section on Biochemical Genetics, Genetics and Biochemistry Branch, National Institute of Diabetes and Digestive and Kidney Diseases, ‡Laboratory of Mammalian Genes and Development, National Institute of Child Health and Development, and §Section on Behavioral Neuropharmacology, Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892; †Institut fu¨r Oganische Chemie und Biochemie der Universita¨tBonn, Gerhard-Domagk-Strasse 1, 53121 Bonn, Germany; and ¶Department of Pathology and Laboratory Medicine, and Neuroscience Center, University of North Carolina, Chapel Hill, NC 27599 Communicated by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, May 12, 1997 (received for review March 21, 1997) ABSTRACT The GM2 activator deficiency (also known as disorder, the respective genetic lesion results in impairment of the AB variant), Tay–Sachs disease, and Sandhoff disease are the the degradation of GM2 ganglioside and related substrates. major forms of the GM2 gangliosidoses, disorders caused by In humans, in vivo GM2 ganglioside degradation requires the defective degradation of GM2 ganglioside. Tay–Sachs and Sand- GM2 activator protein to form a complex with GM2 ganglioside. hoff diseases are caused by mutations in the genes (HEXA and b-Hexosaminidase A then is able to interact with the activator- HEXB) encoding the subunits of b-hexosaminidase A. -
Direct Determination of Sialic Acids in Glycoprotein Hydrolyzates by HPAE-PAD
Application Update 180 Update Application Direct Determination of Sialic Acids in Glycoprotein Hydrolyzates by HPAE-PAD Thermo Fisher Scientific, Inc. INTRODUCTION In this work, sialic acids are determined in five Sialic acids are critical in determining glycoprotein representative glycoproteins by acid hydrolysis followed bioavailability, function, stability, and metabolism.1 by HPAE-PAD. Sialic acid determination by HPAE-PAD Although over 50 natural sialic acids have been identified,2 on a Thermo Scientific™ Dionex™ CarboPac™ PA20 two forms are commonly determined in glycoprotein column is specific and direct, eliminating the need for products: N-acetylneuraminic acid (Neu5Ac) and sample derivatization after sample preparation. The use N-glycolylneuraminic acid (Neu5Gc). Because humans of a disposable gold on polytetrafluoroethylene (Au on do not generally produce Neu5Gc and have been shown PTFE) working electrode simplifies system maintenance to possess antibodies against Neu5Gc, the presence of this compared to conventional gold electrodes while providing sialic acid in a therapeutic agent can potentially lead to an consistent response with a four-week lifetime. The rapid immune response.3 Consequently, glycoprotein sialylation, gradient method discussed separates Neu5Ac and Neu5Gc and the identity of the sialic acids, play important roles in under 10 min with a total analysis time of 16.5 min, in therapeutic protein efficacy, pharmacokinetics, and compared to 27 min using the Dionex CarboPac PA10 potential immunogenicity. column by a previously published method.6,7 By using the Dionex CarboPac PA20 column, the total analysis time is Sialic acid determination can be performed by many reduced, eluent consumption and waste generation are methods. Typically, sialic acids are released from glyco- reduced, and sample throughput is improved. -
Prospects for Using Expression Patterns of Paramyxovirus Receptors As Biomarkers for Oncolytic Virotherapy
cancers Review Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy Olga V. Matveeva 1,* and Svetlana A. Shabalina 2,* 1 Sendai Viralytics LLC, 23 Nylander Way, Acton, MA 01720, USA 2 National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA * Correspondence: [email protected] (O.V.M.); [email protected] (S.A.S.) Received: 27 October 2020; Accepted: 1 December 2020; Published: 5 December 2020 Simple Summary: Some non-pathogenic viruses that do not cause serious illness in humans can efficiently target and kill cancer cells and may be considered candidates for cancer treatment with virotherapy. However, many cancer cells are protected from viruses. An important goal of personalized cancer treatment is to identify viruses that can kill a certain type of cancer cells. To this end, researchers investigate expression patterns of cell entry receptors, which viruses use to bind to and enter host cells. We summarized and analyzed the receptor expression patterns of two paramyxoviruses: The non-pathogenic measles and the Sendai viruses. The receptors for these viruses are different and can be proteins or lipids with attached carbohydrates. This review discusses the prospects for using these paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer. Abstract: The effectiveness of oncolytic virotherapy in cancer treatment depends on several factors, including successful virus delivery to the tumor, ability of the virus to enter the target malignant cell, virus replication, and the release of progeny virions from infected cells. The multi-stage process is influenced by the efficiency with which the virus enters host cells via specific receptors. -
REVIEW the Role and Potential of Sialic Acid in Human Nutrition
European Journal of Clinical Nutrition (2003) 57, 1351–1369 & 2003 Nature Publishing Group All rights reserved 0954-3007/03 $25.00 www.nature.com/ejcn REVIEW The role and potential of sialic acid in human nutrition B Wang1* and J Brand-Miller1 1Human Nutrition Unit, School of Molecular and Microbial Biosciences, University of Sydney, NSW, Australia Sialic acids are a family of nine-carbon acidic monosaccharides that occur naturally at the end of sugar chains attached to the surfaces of cells and soluble proteins. In the human body, the highest concentration of sialic acid (as N-acetylneuraminic acid) occurs in the brain where it participates as an integral part of ganglioside structure in synaptogenesis and neural transmission. Human milk also contains a high concentration of sialic acid attached to the terminal end of free oligosaccharides, but its metabolic fate and biological role are currently unknown. An important question is whether the sialic acid in human milk is a conditional nutrient and confers developmental advantages on breast-fed infants compared to those fed infant formula. In this review, we critically discuss the current state of knowledge of the biology and role of sialic acid in human milk and nervous tissue, and the link between sialic acid, breastfeeding and learning behaviour. European Journal of Clinical Nutrition (2003) 57, 1351–1369. doi:10.1038/sj.ejcn.1601704 Keywords: sialic acid; ganglioside; sialyl-oligosaccharides; human milk; infant formula; breastfeeding Introduction promising new candidate is sialic acid (also known as The rapid growth and development of the newborn infant N-acetylneuraminic acid), a nine-carbon sugar that is a puts exceptional demands on the supply of nutrients. -
A Structure-Based Rationale for Sialic Acid Independent Host-Cell Entry of Sosuga Virus
A structure-based rationale for sialic acid independent host-cell entry of Sosuga virus Alice J. Stelfoxa and Thomas A. Bowdena,1 aDivision of Structural Biology, Wellcome Centre for Human Genetics, University of Oxford, OX3 7BN Oxford, United Kingdom Edited by Peter Palese, Icahn School of Medicine at Mount Sinai, New York, NY, and approved September 9, 2019 (received for review April 23, 2019) The bat-borne paramyxovirus, Sosuga virus (SosV), is one of many myxoviral RBPs consist of an N-terminal cytoplasmic region, paramyxoviruses recently identified and classified within the transmembrane domain, stalk region, and C-terminal six-bladed newly established genus Pararubulavirus, family Paramyxoviridae. β-propeller receptor-binding domain. Paramyxoviral RBPs The envelope surface of SosV presents a receptor-binding protein organize as dimer-of-dimers on the viral envelope, with the (RBP), SosV-RBP, which facilitates host-cell attachment and entry. receptor-binding heads forming dimers and the stalk regions driving Unlike closely related hemagglutinin neuraminidase RBPs from tetramization through disulphide bonding (18–24). Paramyxoviral other genera of the Paramyxoviridae, SosV-RBP and other para- RBPs functionally categorize into three groups: hemagglutinin- rubulavirus RBPs lack many of the stringently conserved residues neuraminidase (HN), hemagglutinin (H), and glycoprotein (G) required for sialic acid recognition and hydrolysis. We determined (25). Unlike HN RBPs, which recognize and hydrolyze sialic the crystal structure of the globular head region of SosV-RBP, acid presented on host cells, H and G RBPs attach to proteinous revealing that while the glycoprotein presents a classical para- receptors, such as SLAMF1 (26–28) and ephrin receptors (29, myxoviral six-bladed β-propeller fold and structurally classifies 30), respectively. -
Liposomal Nanovaccine Containing Α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses Via CD169+ Macrophages and Cdc1
Article Liposomal Nanovaccine Containing α-Galactosylceramide and Ganglioside GM3 Stimulates Robust CD8+ T Cell Responses via CD169+ Macrophages and cDC1 Joanna Grabowska 1,†, Dorian A. Stolk 1,† , Maarten K. Nijen Twilhaar 1, Martino Ambrosini 1, Gert Storm 2,3,4, Hans J. van der Vliet 5,6, Tanja D. de Gruijl 5, Yvette van Kooyk 1 and Joke M.M. den Haan 1,* 1 Department of Molecular Cell Biology and Immunology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Vrije Universiteit Amsterdam, 1081 HZ Amsterdam, The Netherlands; [email protected] (J.G.); [email protected] (D.A.S.); [email protected] (M.K.N.T.); [email protected] (M.A.); [email protected] (Y.v.K.) 2 Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands; [email protected] 3 Department of Biomaterials Science and Technology, University of Twente, 7500 AE Enschede, The Netherlands 4 Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore 5 Department of Medical Oncology, Amsterdam UMC, Cancer Center Amsterdam, Amsterdam Infection and Immunity Institute, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands; [email protected] (H.J.v.d.V.); [email protected] (T.D.d.G.) 6 Lava Therapeutics, 3584 CM Utrecht, The Netherlands * Correspondence: [email protected]; Tel.: +31-20-4448080 Citation: Grabowska, J.; Stolk, D.A.; † Authors contributed equally. Nijen Twilhaar, M.K.; Ambrosini, M.; Storm, G.; van der Vliet, H.J.; Abstract: Successful anti-cancer vaccines aim to prime and reinvigorate cytotoxic T cells and should de Gruijl, T.D.; van Kooyk, Y.; therefore comprise a potent antigen and adjuvant.